FDA Issues Risk Warning for Nationwide Coffee Recall
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Food inspectors have issued a nationwide recall of coffee pods due to concerns that the ink on the pods' lids may run when exposed to high temperatures.
New Mexico Pinon Coffee recalled 154 units of its Dark Pinon Single Serve 10-count coffee pods after the U.S. Food and Drug Administration (FDA) determined the manufacturing defect.
CinFranky LLC, doing business as New Mexico Pinon Coffee in Albuquerque, New Mexico, voluntarily initiated the recall, which began on June 20, 2025.
Newsweek reached out to the company via email on Wednesday for comment.
Why It Matters
The FDA assigned this recall a "Class III" designation, the lowest risk level used by the agency. This classification applies to situations where the use or exposure to the recalled product is not likely to cause adverse health consequences.
While the FDA determined the risk to be minimal, the corrective move underscores the regulatory attention to food contact safety and manufacturing consistency.
Stock photo of spilled coffee grounds leaking from an opened coffee pod.
Stock photo of spilled coffee grounds leaking from an opened coffee pod.
Getty Images
What To Know
The recall targets 154 units of New Mexico Pinon Coffee's Dark Pinon Single Serve 10-count cups. Each cup was sold with the specific identifier "Product Number: F03308 UPC:812361033081," lot code 251749, and a best-by date of May 8, 2026.
The affected pods are compatible with single-serving brewing systems and contain ground coffee with natural flavors.
CinFranky LLC voluntarily initiated the recall and began notifying affected consignees using a combination of email, fax, letter, telephone, and possible site visits, an FDA notice said.
Consumers in possession of the affected pods should consult the FDA's official recall listing for details. Consumers are advised to refrain from using pods with the specified UPC, lot code, and best-by date, and to contact the manufacturer or place of purchase for additional information on returns or refunds.
In March, a voluntary recall was issued by Massimo Zanetti Beverage USA for 692 cases of ground coffee in 15 states after some of the products were found to be mislabeled as decaffeinated.
What People Are Saying
The FDA, in its report: "Clear coat seal on the lid of the single serve cups did not get applied consistently to all cups in the production run. This resulted in the food safe ink printing on some cups to run when exposed to high temperature, high-pressure water used in a K-cup machine."
What Happens Next
The recall remains active and ongoing. The FDA will continue to monitor this enforcement action, and CinFranky LLC is expected to complete its notification process and removal of affected product batches. Consumers can follow updates through the FDA's Enforcement Report database.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 hours ago
- Business Upturn
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) — Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: FolqsContact Person: David Johnson Email: [email protected] Phone: 800-975-4495Country: United States Website:
Yahoo
10 hours ago
- Yahoo
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment
Bausch Health Companies Inc. (NYSE:BHC) is one of the most undervalued Canadian stocks to buy now. On July 29, Bausch Health Companies announced a definitive agreement to acquire DURECT Corporation (NASDAQ:DRRX). The acquisition is valued at ~$63 million upfront with potential for an additional $350 million in sales milestone payments, and will be an all-cash transaction. Bausch Health is acquiring DURECT primarily for its lead asset, called larsucosterol. This novel therapeutic molecule is an epigenetic modulator that the FDA has granted Breakthrough Therapy Designation for the treatment of alcoholic hepatitis/AH, which is a life-threatening form of alcohol-associated liver disease. A closeup of pills in a pharmacy, representing the high quality medications of the company. AH is characterized by severe liver inflammation & necrosis and accounted for ~164,000 hospital admissions in the US in 2021. There are currently no FDA or European Medicines Agency/EMA-approved treatments for the condition. The acquisition of larsucosterol strengthens Bausch Health's commitment to hepatology. Bausch Health plans to use its expertise to advance larsucosterol through a planned Phase 3 program. Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharmaceutical and medical device company that develops, manufactures, and markets products in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, OTC products, aesthetic medical devices, and eye health. DURECT Corporation (NASDAQ:DRRX) is a late-stage biopharmaceutical company that develops epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, such as acute organ injury. While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Associated Press
10 hours ago
- Associated Press
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder. This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: Folqs Contact Person: David Johnson Email: [email protected] Phone: 800-975-4495 Country: United States Website: Media Contact Company Name: Folqs Contact Person: David Johnson Email: [email protected] Phone: 800-975-4495 Country: United States Website:
